---
id: asco-gastric-2024
title: "ASCO Guideline: Systemic Therapy for Local-Regional and Advanced Gastric/Gastroesophageal Junction Adenocarcinoma"
short_title: "Gastric Cancer Systemic Therapy"
organization: American Society of Clinical Oncology
country: United States
url: https://ascopubs.org/doi/10.1200/JCO.23.02465
specialty: oncology
guideline_type: clinical-practice
evidence_system: asco
conditions:
  - Gastric Adenocarcinoma
  - Gastroesophageal Junction Cancer
  - GEJ Cancer
tags:
  - gastric cancer
  - gastrointestinal cancer
  - immunotherapy
  - HER2
  - chemotherapy
publication_date: 2024-06-15
previous_version_date: 2022-07-20
status: current
supersedes: asco-gastric-2022
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for systemic therapy in patients with resectable, locally advanced unresectable, and metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.

## Key Recommendations

### Biomarker Testing
- HER2 testing: All patients with advanced disease
- PD-L1 CPS testing for immunotherapy eligibility
- MSI-H/dMMR testing
- Claudin 18.2 testing when available

### Resectable Disease - Perioperative Therapy
- FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) recommended
- Perioperative chemoimmunotherapy under investigation
- Neoadjuvant chemotherapy improves resectability and survival

### Locally Advanced Unresectable
- Definitive chemoradiation or systemic chemotherapy
- Reassess for resectability with response
- Clinical trial participation encouraged

### First-Line Metastatic - HER2 Negative
- Fluoropyrimidine + platinum + nivolumab (PD-L1 CPS â‰¥5)
- Fluoropyrimidine + platinum for PD-L1 CPS <5
- FOLFOX, CAPOX, or FOLFIRI-based regimens

### First-Line Metastatic - HER2 Positive
- Trastuzumab + pembrolizumab + chemotherapy
- Trastuzumab + chemotherapy if immunotherapy not feasible

### Second-Line and Beyond
- Ramucirumab-containing regimens (paclitaxel + ramucirumab)
- Trastuzumab deruxtecan for HER2+ disease
- MSI-H: Pembrolizumab
- Claudin 18.2+: Zolbetuximab (when available)
- Best supportive care appropriately integrated
